We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

101 hedge funds and large institutions have $248M invested in UroGen Pharma in 2023 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 35 increasing their positions, 22 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 8

105% more call options, than puts

Call options by funds: $1.04M | Put options by funds: $509K

82% more capital invested

Capital invested by funds: $137M → $248M (+$112M)

59% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 22

19% more funds holding

Funds holding: 85 → 101 (+16)

2.2% more ownership

Funds ownership: 56.33% → 58.53% (+2.2%)

Holders
101
Holders Change
+16
Holders Change %
+18.82%
% of All Funds
1.6%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
24
Increased
35
Reduced
22
Closed
8
Calls
$1.04M
Puts
$509K
Net Calls
+$533K
Net Calls Change
+$640K

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$42.1M
2
RCM
RA Capital Management
Massachusetts
+$23.8M
3
SCM
Silverarc Capital Management
Massachusetts
+$8.17M
4
SCM
Soleus Capital Management
Connecticut
+$5.97M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$3.33M

Top Sellers

Rank Fund Capital Flow
1
CI
Clal Insurance
Israel
-$4.93M
2
SCM
Stonepine Capital Management
Oregon
-$4.64M
3
OM
Opaleye Management
Massachusetts
-$4.01M
4
MMH
Menora Mivtachim Holdings
Israel
-$3.64M
5
Wells Fargo
Wells Fargo
California
-$3.39M
Name Holding Trade Value Shares
Change 		Change in
Stake
SSA
26
Schonfeld Strategic Advisors
New York
$1.82M +$2.09M +130,200 New
CSS
27
Cubist Systematic Strategies
Connecticut
$1.82M +$1.89M +117,718 +953%
Two Sigma Investments
28
Two Sigma Investments
New York
$1.68M +$1.61M +100,399 +507%
Vanguard Group
29
Vanguard Group
Pennsylvania
$1.57M +$193K +12,019 +12%
Morgan Stanley
30
Morgan Stanley
New York
$1.56M +$773K +48,174 +77%
MIH
31
Meitav Investment House
Israel
$1.29M -$226K -14,056 -13%
Ameriprise
32
Ameriprise
Minnesota
$1.21M +$17.2K +1,069 +1%
AC
33
Annandale Capital
Texas
$1.15M -$40.1K -2,500 -3%
RHJA
34
Rice Hall James & Associates
California
$1.05M -$14.6K -907 -1%
Wellington Management Group
35
Wellington Management Group
Massachusetts
$982K +$1.12M +70,063 New
N
36
Nuveen
North Carolina
$892K +$34.9K +2,172 +4%
Bank of New York Mellon
37
Bank of New York Mellon
New York
$810K +$191K +11,886 +26%
Goldman Sachs
38
Goldman Sachs
New York
$752K +$357K +22,264 +71%
Charles Schwab
39
Charles Schwab
California
$650K +$26.8K +1,670 +4%
Bank of America
40
Bank of America
North Carolina
$607K +$189K +11,759 +37%
CBA
41
Coastal Bridge Advisors
Connecticut
$539K +$12.3K +768 +2%
BRA
42
Bender Robert & Associates
California
$486K – – –
D.E. Shaw & Co
43
D.E. Shaw & Co
New York
$471K +$540K +33,633 New
SAM
44
Shikiar Asset Management
New York
$466K – – –
Connor, Clark & Lunn Investment Management (CC&L)
45
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$417K +$133K +8,260 +38%
JF
46
Jump Financial
Illinois
$415K +$475K +29,600 New
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$376K +$104K +6,458 +32%
Marshall Wace
48
Marshall Wace
United Kingdom
$376K -$964K -60,059 -69%
BP
49
BBR Partners
New York
$364K – – –
PAI
50
Palo Alto Investors
California
$343K – – –
1
2
3 4 5

URGN Hedge Fund Activity: Q3 2023 in Review

101 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q3 2023, worth a combined $248M — up 82% from $137M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new URGN positions and 8 closed out — a net gain of 16 holders — while 35 added to existing stakes and 22 trimmed.

The largest buyer was Great Point Partners, opening a new position worth an estimated $42.1M. The largest seller was Clal Insurance, cutting an estimated $4.93M.

  • 101 institutional investors held UroGen Pharma (URGN) as of Q3 2023, up from 85 in Q2 2023.
  • Funds reported $248M of UroGen Pharma stock for Q3 2023, up 82% quarter-over-quarter.
  • 24 funds opened new UroGen Pharma positions in Q3 2023 and 8 closed out, a net change of +16 holders.
  • The largest UroGen Pharma buyer in Q3 2023 was Great Point Partners, an estimated $42.1M added.
  • The largest UroGen Pharma seller in Q3 2023 was Clal Insurance, an estimated $4.93M sold.

Based on aggregated 13F filings for Q3 2023.